Background:
The adrenal glands are 2 small organs that sit on top of each kidney. They release hormones; these are chemicals that control how the body works. Tumors on or outside the adrenal glands are called functional if they release hormones; they are called nonfunctional if they do not. Doctors who treat adrenal tumors need to know which type a person has. Researchers want to find better ways to learn whether an adrenal tumor is functional.
Objective:
To see if a new radioactive tracer ([68Ga]Ga-PentixaFor) can make it easier to identify functional adrenal tumors with positron emission tomography (PET) scans.
Eligibility:
People aged 18 years and older with 1 or more adrenal tumors. They must have increased levels of the hormones aldosterone or cortisol. They must also be enrolled in at least 1 other related NIH study (protocols 19-DK-0066, 18-CH-0031, or 09-C-0242).
Design:
Participants will be screened. They may have imaging scans. Their ability to perform normal activities will be reviewed.
Participants will have one PET scan with the study tracer.
The tracer will be given through a tube attached to a needle inserted into a vein. Participants will receive the tracer 1 hour before the scan. They will lie still on a bed while a machine captures images of the inside of their body. The scan will take 45 to 90 minutes.
Participants heart rate, blood pressure, and rate of breathing will be checked before, during, and after the scan.
Participants will have a follow-up visit 3 days after their scan. This visit can be by phone, email, or in person.

开始日期2024-09-23

申办/合作机构

National Cancer Institute

NCT06478875

/ Not yet recruiting临床2期IIT

"Pilot Study for the Evaluation of [68Ga]Ga-PentixaFor PET Imaging for the Identification of Unilateral Adrenal Secretion of ALdosterON in Patients With Primary Aldosteronism"

PentixaFor radiolabeled with 68Gallium (68Ga) is a radiopharmaceutical targeting the CXC chemokine receptor 4 (CXCR4) receptor. The CXCR4 receptor is expressed in zona glomerulosa of the adrenal cortex and in aldosterone producing adenoma (APA). The objective of this study will be to evaluate in 25 patients if [68Ga]Ga-PentixaFor positron emission tomography ([68Ga]Ga-PTF-PET) imaging allows for the discrimination of patients with lateralized or non-lateralized secretion of aldosterone in adrenal glands classified based on adrenal vein sampling (AVS).

开始日期2024-06-01

申办/合作机构

Assistance Publique des Hôpitaux de Paris SA

[+1]

CTIS2022-500918-25-00

/ Recruiting临床3期

A pivotal phase 3 clinical trial to assess the diagnostic performance and safety of [68Ga]Ga-PentixaFor ([68Ga]Ga-PTF), a positron emission tomography (PET) imaging agent, versus [18F]FDG PET/CT imaging, for staging of patients with confirmed marginal zone lymphoma (MZL) exemplary for CXCR4-positive malignant lymphomas: a prospective, international, multi-center, comparative, randomized, cross-over, open-label lymphoma diagnostic trial (LYMFOR). - PTF301

开始日期2024-05-20

申办/合作机构

PentixaPharm GmbH

100 项与 [68Ga] Pentixafor 相关的临床结果

登录后查看更多信息

100 项与 [68Ga] Pentixafor 相关的转化医学

登录后查看更多信息

100 项与 [68Ga] Pentixafor 相关的专利（医药）

登录后查看更多信息

134

项与 [68Ga] Pentixafor 相关的文献（医药）

2025-06-01·CLINICAL NUCLEAR MEDICINE

68Ga-Pentixafor PET/CT–Based Response Evaluation and its Prognostic Value in Multiple Myeloma: Comparison With IMWG and 18F-FDG–Based Response

Article

作者: Watts, Ankit ; Kumar, Suraj ; Kaur, Harneet ; Singh, Baljinder ; Malhotra, Pankaj ; Kumar, Rajender ; Sreedharanunni, Sreejesh ; Sachdeva, Man Updesh Singh ; Singh, Charanpreet

Purpose::

68Ga-Pentixafor PET/CT targets CXCR4 receptors and provides superior diagnostic accuracy in multiple myeloma (MM) compared with 18F-FDG PET/CT. However, its role in response evaluation remains unexplored. We propose a 68Ga-Pentixafor PET/CT–based response evaluation criterion and evaluate its utility compared with International Myeloma Working Group (IMWG) criteria and 18F-FDG PET/CT–based response.

Patients and Methods::

In this prospective single-center study, 40 treatment-naive myeloma patients were recruited between February 2021 and April 2023. Both 68Ga-Pentixafor and 18F-FDG PET/CT were performed at baseline and at follow-up (7.2 mo-median). Response to treatment was evaluated using the proposed 68Ga-Pentixafor PET/CT criteria and compared with responses assessed by IMWG and 18F-FDG PET/CT. Progression-free survival (PFS) and overall survival (OS) were analyzed and compared using Kaplan-Meier survival curves.

Results::

Among the 40 newly diagnosed MM patients [median age: 56.5 years (IQR 45.25 to 63.75); 24 men], 68Ga-Pentixafor PET/CT was positive in a greater proportion of patients than 18F-FDG PET/CT [90% (36/40) vs. 67.5% (27/40); P=0.02] thus, adequately evaluated response in additional 27.5% (11/40) of cases. Using the proposed criteria for 68Ga-Pentixafor PET/CT, significant differences in PFS were observed across response categories [complete response (CR)—not reached, partial response (PR)—26.2 mo, progressive disease (PD)–15.3 mo; P=0.001]. Among patients achieving ≥very good partial response (VGPR) as per IMWG, those with positive 68Ga-Pentixafor PET/CT had shorter PFS compared with those with negative findings (median PFS: 34.2 mo vs. not reached; P=0.056), whereas no significant difference was noted with 18F-FDG PET/CT (P=0.68). In addition, on follow-up of patients with negative 18F-FDG at the response, those with discordant 68Ga-Pentixafor findings had significantly shorter PFS (17.73 mo vs. not reached; P=0.010) compared with those with concordant negative findings.

Conclusions::

68Ga-Pentixafor PET/CT offers a more accurate assessment of treatment response and prognosis in MM patients, adding valuable information beyond the IMWG and 18F-FDG PET/CT–based criteria.

2025-05-01·NUCLEAR MEDICINE AND BIOLOGY

Longitudinal multi-tracer imaging of hepatocellular carcinoma identifies novel stage- and oncogene-specific changes

Article

作者: Lolatte, Kelsey ; Bengel, Frank M ; Balakrishnan, Asha ; Hu, Yuhai ; Ross, Tobias L ; Teuter, Mari ; Ott, Michael ; Bankstahl, Jens P

BACKGROUND:

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths, globally. There is a need for novel biomarkers for early detection and novel, effective targeted therapies. Molecular imaging can faithfully visualize, characterize and quantify specific relevant biological processes.

BASIC PROCEDURE:

We performed longitudinal dedicated small-animal positron emission tomography-computed tomography (PET/CT) imaging to analyze changes in glucose metabolism using [¹⁸F]fluorodeoxyglucose ([¹⁸F]FDG), amino acid turnover with [¹⁸F]fluoroethyltyrosine ([¹⁸F]FET), and chemokine receptor expression using [⁶⁸Ga]pentixafor targeting CXCR4, during stages of early tumor development, overt HCC and regression. We used two conditional transgenic mouse models of HCC, driven by clinically relevant oncogenes c-MYC (LT2/MYC) or HRASV12 (LT2/RAS). Conditional doxycycline-regulated mouse models, enable liver-specific oncogene activation or inhibition, leading to liver tumor development and regression, respectively. Correlation of our PET/CT findings with our gene expression and metabolomics data and with histological analyses followed.

MAIN FINDINGS:

We show PET/CT identifies HCC stage-specific and oncogene-specific molecular changes that may serve as potential novel biomarkers and therapeutic targets. Glucose metabolism and CXCR4 chemokine expression are differentially deregulated during HCC development in an oncogene-specific manner. Our [¹⁸F]FDG results correlated with glucose transporter GLUT1 gene expression and with our metabolomics data. Increased expression of CXCR4 and CD68 inflammatory markers mirrored [⁶⁸Ga]pentixafor results in LT2/MYC mice. FET-based measurement of amino acid turnover are insensitive to stages of HCC-development, in our studies. Concurrently, no significant changes in expression of tyrosine metabolism genes were observed.

PRINCIPAL CONCLUSIONS:

Our study highlights that identified changes in targeted molecular imaging can facilitate a better understanding of underlying biological processes and may help guide novel oncogene-specific targeted anti-tumor therapies in HCC, with promising translational potential.

2025-04-01·ACADEMIC RADIOLOGY

A Prospective Evaluation of Chemokine Receptor-4 (CXCR4) Overexpression in High-grade Glioma Using 68Ga-Pentixafor (Pars-Cixafor™) PET/CT Imaging

Article

作者: Dadgar, Habibollah ; Jafari, Esmail ; Ricci, Maria ; Al-Alawi, Haider Muhsin ; Al-Ibraheem, Akram ; Haidar, Mohamad ; Arabi, Hossein ; Marafi, Fahad ; Al-Balooshi, Batool ; Assadi, Majid ; Norouzbeigi, Nasim ; Cimini, Andrea ; Usmani, Sharjeel ; Omar, Yehia ; Zaidi, Habib ; Esmail, Abdulredha A

BACKGROUND:

While magnetic resonance imaging (MRI) remains the gold standard for morphological imaging, its ability to differentiate between tumor tissue and treatment-induced changes on the cellular level is insufficient. Notably, glioma cells, particularly glioblastoma multiforme (GBM), demonstrate overexpression of chemokine receptor-4 (CXCR4). This study aims to evaluate the feasibility of non-invasive ⁶⁸Ga-Cixafor™ PET/CT as a tool to improve diagnostic accuracy in patients with high-grade glioma.

METHODS:

In this retrospective analysis, a database of histopathology-confirmed glioma patients with MRI findings consistent with high-grade gliomas was utilized. Within 2 weeks of their MRI, these patients underwent ⁶⁸Ga-Cixafor™ PET/CT scans to assess CXCR4 expression. Both visual scoring based on established criteria and semi-quantitative measures including maximum standardized uptake value (SUV_max) and tumor-to-background ratios (TBR) were calculated to analyze the PET/CT data.

RESULTS:

Our retrospective study enrolled 29 histologically confirmed glioma patients with MRI findings consistent with high-grade gliomas. All patients underwent ⁶⁸Ga-Cixafor™ PET/CT scans within 2 weeks of their MRI, specifically at one-hour post-injection time point. Visual assessment based on a standardized scoring system identified 27 positive scans out of 29 (93.1%). Median SUV_max was 2.31 (range: 0.49-9.96) and median TBR was 20 (range: 6.12-124.5). Pathological analysis revealed 5 grade III (17.24%) and 24 grade IV (82.75%) lesions among the 29 patients. Notably, the median SUV_max of grade IV lesions (2.85) was significantly higher than grade III lesions (1.27) (P=0.02). Conversely, there was no significant difference in median TBR between grade IV (20) and grade III (22.37). These findings support the correlation between high CXCR4 expression, particularly in high-grade gliomas, and elevated uptake of ⁶⁸Ga-Pentixafor. While areas with high uptake showed CXCR4 expression, areas with low uptake did not exhibit noticeable expression (data not shown).

CONCLUSION:

This study demonstrated that ⁶⁸Ga-Cixafor™ PET exhibits a TBR with minimal cortical uptake, significantly enhancing glioma detection compared to conventional imaging methods. This, combined with the potential therapeutic capabilities of CXCR4-targeting radiopharmaceuticals, highlights the promise of ⁶⁸Ga-Cixafor™ as a valuable tool for not only improved glioma diagnosis but also personalized treatment strategies.

项与 [68Ga] Pentixafor 相关的新闻（医药）

2025-05-06

·创药网

【技术剖析】技术革新驱动核药产业系统性创新（二）

近年来，核药领域迎来爆发式增长。在精准医疗与诊疗一体化理念驱动下，核药创新技术加速升级，呈现出"核素迭代、靶标拓展、平台创新"等创新趋势。新型α核素药物、新功能靶向分子、智能开发平台等技术突破正重塑核药研发范式。本文概述了传统靶标优化及新兴靶标拓展、创新型放射性标记核药平台，供研发人员参考。近年来，核药领域迎来爆发式增长。据统计，2024年核药市场规模达175亿美元，复合增长率13.48%，全球临床阶段核药管线超600项。在精准医疗与诊疗一体化理念驱动下，核药创新技术加速升级，呈现出"核素迭代、靶标拓展、平台创新"等创新趋势。新型α核素药物、新功能靶向分子、智能开发平台等技术突破正重塑核药研发范式。随着诺华Pluvicto在转移性去势抵抗性前列腺癌治疗中的成功，核药产业竞争焦点已从同位素选择转向系统性技术革新。三、传统靶标优化及新兴靶标拓展一直以来，靶向生长抑素受体（SSTR）和PSMA的药物一直是放射治疗诊断学领域的“明星产品”。目前在研药物的热门靶标还包括：CXC族趋化因子受4（CXCR4）、成纤维母细胞活化蛋白（FAP）、人类表皮受体生长因子2（HER2）和神经降压素受体（NTR）等。其中，PSMA是当前核药研发的最热门靶标，涉及项目数量最多，覆盖前列腺癌、乳腺癌及2024年新进入临床阶段的项目。紧随其后的胃泌素释放肽受体（GRPR）、神经营养因子受体酪氨酸激酶（NTRK）靶标也展现出较高的研发活跃度，主要聚焦于肺癌、胃癌和神经内分泌瘤等适应症。111In-ProstaScint是FDA最早批准上市（1996年获批）的靶向PSMA的前列腺癌放射性诊断药物。环五肽68Ga-Pentixafor是目前研究最深入的靶向CXCR4的分子探针，应对治疗所用的化合物为Pentixather。FAP是肿瘤精准诊疗颇具潜力的理想靶标，目前一些靶向FAP放射性药物被广泛研究。传统靶标如诺华靶向PSMA的Pluvicto已获批用于转移性去势抵抗性前列腺癌（mCRPC），现已拓展至早期激素敏感性前列腺癌（mHSPC）；另有研究使用Pluvicto联合PARP抑制剂奥拉帕利治疗BRCA突变患者；最重要的是随着α核素升级，治疗效果有所提升。针对SSTR2的优化也包括适应症的扩展，如诺华的Lutathera以及远大医药的¹⁷⁷Lu-DOTA-TATE已在脑膜瘤、小细胞肺癌及胶质瘤领域开始开展临床试验。值得关注的是，随着研究的不断深入，越来越多的新靶标逐渐进入科研人员的视野，核药的靶标选择正从传统的PSMA、SSTR向更具潜力的新兴靶标拓展（图2）。包括FAP在泛癌种中的治疗潜力。数据显示，68Ga-FAPI PET显像在肝癌中的灵敏度超90%；诺华的177Lu-FAP-2286的作用机制为依靠177Lu靶向FAP阳性肿瘤细胞以及周围的FAP阴性肿瘤细胞，从而导致DNA损伤和细胞死亡，目前，该药正在进行I期临床试验，用于广谱肿瘤治疗。当前核药管线中FAP-α临床前项目有42项，显示出较高的热度。国内北京大学团队也提出了靶向共价放射性药物（CTR）的理念，开发共价FAP探针（CTR-FAPI），在早期研究中，放药68Ga-CTR-FAPI PET-CT，显著提高了对甲状腺髓样癌病灶的灵敏度；治疗功能方面，国内蓝纳成生物启动了1项FAP靶标诊疗一体化临床试验（CTR20240127），评价177Lu-LNC1004注射液在FAP阳性的晚期恶性实体瘤患者中的安全性和耐受性。其它靶标方面，针对CXCR4的研究主要在血液系统肿瘤（如淋巴瘤）和神经内分泌肿瘤的显像。68Ga-pentixafor针对多种疾病包括边缘区淋巴瘤等多种肿瘤显像已进入Ⅲ期临床试验。90Y-pentixather和177Lu-pentixather主要用于治疗多发性骨髓瘤、T细胞淋巴瘤、惰性非霍奇金淋巴瘤等处于I/Ⅱ期临床阶段。此外，203Pb-pentixather和212Pb-pentixather等药物处于I期临床试验。针对PD-L1（程序性死亡配体1）的研究，主要表现在免疫治疗协同的潜力明显，有研究开发的全D型多肽核药[⁶⁴Cu/⁶⁸Ga]DPA，实时监测PD-L1表达，可指导免疫治疗患者分层。另有临床研究显示放射性核素标记PD-L1抗体（如¹⁷⁷Lu-atezolizumab）联合PD-1抑制剂，黑色素瘤ORR提升至65%。当前，PD-L1在临床前及I期临床占比高，显示出较强的潜力。另有一些低活跃度靶标的研发如CA9（碳酸酐酶IX）主要针对肾细胞癌和低氧相关肿瘤。远大医药的TLX250-CDx（靶向CA9）海外Ⅲ期临床呈现积极数据，已在国内开始I期临床试验首例入组；故可开发CA9特异性放射性治疗药物，用于低氧耐药性肿瘤的精准治疗。核药在靶标选择上，肿瘤的表面受体蛋白仍然是最受到关注的靶标类型。随着对肿瘤生物学和疾病机制的深入研究，越来越多的潜在靶标被发现，如一些与肿瘤微环境、免疫调节相关的靶标逐渐受到关注，有望为核药研发提供更多的方向和机会。AB图2：2024年活跃的核药项目Top20靶标（A按总数排序；B按已公布研究阶段分布）四、创新型放射性标记核药平台1. 高效放射性标记平台技术Radiopharm Theranostics是一家专注于放射性药物开发的临床阶段生物技术公司，核心策略是通过靶向放射性核素治疗（TRT）与诊疗一体化技术，解决实体瘤治疗中的靶向性、疗效与安全性难题。其核心技术包括高亲和力放射性螯合剂（High-Affinity Radiometal Chelators）与靶向纳米粒子传输（Targeted Nanoparticle Delivery），可实现更稳定的放射性核素偶联，并减少体内非特异性分布，形成差异化竞争优势，在诊疗一体化与泛癌种适应症拓展上展现出显著优势。2. AI+精准放射性药物平台配体的结构设计和修饰是解决放射性药物缺乏问题的关键要素。人工智能（AI）在预测生物分子的三维结构、指导新型放射性药物的合成方面不断取得突破（图3）。放射性配体治疗研究存在结合亲和力不足、靶标筛选和分子优化难度大等局限，AI可以准确预测所设计蛋白质的结构，在此基础上，根据结合位点氨基酸侧链的取向，设计出可以准确结合的蛋白质，实现更好的结合亲合力，将配体、螯合剂、放射性核素整体作AI设计，得到结构稳定性的全新结构。AI技术通过‌数据整合能力‌（跨模态数据关联）、‌计算模拟效率‌（减少实验试错）、‌动态优化能力‌（实时调整研发路径），能够缩短放射性药物研发周期，同时提高成功率并降低成本，推动诊疗一体化发展。图3：AI赋能核药开发概念图3. 预靶向技术预靶向（pre-targeting）技术是指先注射特异性抗体，使其在肿瘤部位积累，再注射小分子放射性配体，使其与已积累的抗体发生自连接，从而实现疾病显像和治疗。与传统核药相比，预靶向药物兼具抗体靶向肿瘤的特异性和放射性标记小分子的药代动力学特征，有效减少了放射性核素的体内循环时间，降低了体内的总辐射吸收剂量，堪称基于抗体的传统放射免疫疗法的升级替代版。在该系统中，首先给药的是带有标签的非放射性标记抗体。抗体在足够的时间从血液中消除后，使用可与标签结合的放射性标记的二次剂，通常采用低分子量化合物作为二次剂。希望抗体不被内化，体内偶联发生在癌细胞的膜上。由于放射性核素可以独立于抗体的缓慢积累而被递送，因此，在该系统中可以实现血液放射性水平非常低的放射免疫检测（RID）和放射免疫治疗（RIT）。这种方法需要非常有效和选择性的结合。当前，已报道了四类预靶向系统：链霉亲和素-生物素非共价结合途径、双特异性抗体结合抗原-放射性标记半抗原途径、基于生物正交-点击化学的抗体预靶向途径、寡聚核苷酸链互补杂交途径。其中，前两者已率先进入临床研究阶段。预靶向核医学显像和治疗在减少非肿瘤组织辐射剂量方面展现出巨大潜力，但要让该技术在临床大放异彩，还需克服免疫原性、血液毒性、模块化等难题。随着研究的不断深入，预靶向策略必将在癌症治疗领域发挥越来越重要的作用，为患者带来更加精准、高效的治疗方案。4. 创新性诊疗一体化平台核药诊疗一体化平台通过放射性核素标记的分子探针（如68Ga/177Lu标记的PSMA等）实现疾病精准诊断与治疗的协同系统，其核心在于利用同一靶向分子实现病灶可视化（如PET显像）与放射性内照射治疗的时空统一，从而提升肿瘤等重大疾病的个体化诊疗效率。当前，国内外诊疗一体化平台的创新点集中体现在多模态影像融合与智能决策支持的深度结合，例如GE医疗与诺华合作建立的放射配体诊疗中心，通过整合分子影像诊断（如68Ga/18F标记探针）与放射配体治疗（如177Lu-PSMA-617），优化前列腺癌患者的全周期诊疗路径；罗氏通过构建肝癌用药预测模型和淋巴瘤数字化系统工具，将数据驱动决策融入临床实践，提升治疗精准度；脉购健康管理系统则通过整合电子病历、健康监测数据等构建患者全息画像，支持远程随访与动态干预。未来趋势将聚焦三大方向：一是诊疗场景向早期预防延伸，如GE医疗Max Apollo PET/CT设备通过AI算法实现1.4mm空间分辨率和3分钟全身扫描，提升阿尔茨海默病等疾病的早期筛查能力；二是核素技术突破驱动精准治疗，包括α核素（225Ac）在实体瘤中的应用扩展及双核素动态剂量调控系统；三是全球化诊疗网络构建，依托自动化生产基地与云平台实现“本地化生产-快速配送-治疗”闭环，例如诺华与GE医疗共建的放射配体疗法生产基地已覆盖中国浙江海盐等地。总的来看，全球核药正快速从“诊断为主”向“诊疗一体”转型，α核素药物因其高能短程的特性，成为研究热点。同时，靶标选择不断拓展，从传统的PSMA、SSTR逐步延伸至FAP-α、CXCR4、PD-L1等新兴靶标；随着放射性核素生产、药物递送系统和伴随诊断技术的进步，全球核药管线快速丰富，多个品种已进入临床后期，标志着核药开始迈入产业化加速期。参考资料：1. Beacon Radiopharma. The Future of Radiopharmaceuticals: 2024 Review & 2025 Outlook.2. Insight数据库，检索日期：2025年4月.3. 动脉新医药、药渡、谈思生物网络公开报道.本文其它内容请见创药网https://www.iddds.cn

放射疗法

100 项与 [68Ga] Pentixafor 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
边缘区B细胞淋巴瘤	临床3期	奥地利	PentixaPharm GmbH	2024-05-20
边缘区B细胞淋巴瘤	临床3期	法国	PentixaPharm GmbH	2024-05-20
边缘区B细胞淋巴瘤	临床3期	德国	PentixaPharm GmbH	2024-05-20
边缘区B细胞淋巴瘤	临床3期	意大利	PentixaPharm GmbH	2024-05-20
边缘区B细胞淋巴瘤	临床3期	西班牙	PentixaPharm GmbH	2024-05-20
醛固酮增多症	临床3期	-	PentixaPharm GmbH	-
原发性中枢神经系统淋巴瘤	临床2期	丹麦	PentixaPharm GmbH	2022-10-05
原发性中枢神经系统淋巴瘤	临床2期	法国	PentixaPharm GmbH	2022-10-05
继发性中枢神经系统淋巴瘤	临床2期	丹麦	PentixaPharm GmbH	2022-10-05
继发性中枢神经系统淋巴瘤	临床2期	法国	PentixaPharm GmbH	2022-10-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EANM2024	N/A	软组织感染 CXCR4 receptors	20	Ga-Pentixafor (Chronic periprosthetic infections (PPI))	廠鏇淵鬱鹹顧製蓋廠糧(鏇糧壓鏇觸網願願製餘) = 遞窪構壓顧構鏇積鹽網廠獵襯網願襯鬱糧構夢 (鑰鹹製製鹹窪醖築糧網 ) 更多	积极	2024-09-27
EANM2024	N/A	软组织感染 CXCR4 receptors	20	Ga-Pentixafor (Diabetic foot infections (DFI))	廠鏇淵鬱鹹顧製蓋廠糧(鏇糧壓鏇觸網願願製餘) = 築壓糧餘選鹹窪廠鹽膚廠獵襯網願襯鬱糧構夢 (鑰鹹製製鹹窪醖築糧網 ) 更多	积极	2024-09-27
EANM2024	N/A	醛固酮增多症	-	68Ga-Pentixafor (Single PET model)	鑰觸鹽鹽醖廠觸廠願糧(糧蓋遞範齋窪餘齋淵蓋) = 蓋網衊襯鑰構鹹壓製糧壓構願壓鏇艱醖鑰糧製 (積獵鑰製鑰淵窪願鹹鏇 )	积极	2024-09-27
ENDO2024	N/A	肾上腺皮质腺瘤	30	[68Ga]Ga-Pentixafor68Ga-Pentixaforafor (68Ga-Pentixafor PET/CT)	糧遞簾壓積積壓衊製製(遞廠鏇醖餘艱範繭積網) = 構鑰窪醖鹽窪糧膚夢淵廠遞廠選鏇鑰觸蓋膚築 (壓鑰鹽襯壓糧獵鬱齋觸 ) 更多	-	2024-06-01
ENDO2024	N/A	肾上腺皮质腺瘤	30	[68Ga]Ga-Pentixafor (Adrenal vein sampling (AVS))	糧遞簾壓積積壓衊製製(遞廠鏇醖餘艱範繭積網) = 選選鏇選觸襯顧顧製餘廠遞廠選鏇鑰觸蓋膚築 (壓鑰鹽襯壓糧獵鬱齋觸 ) 更多	-	2024-06-01
Pubmed \| J Clin Endocrinol Metab	N/A	醛固酮增多症	-	68Ga-Pentixafor (Aldosterone-producing adenoma (APA))	製顧襯願鏇齋衊蓋壓艱(糧網襯鹽遞鏇網鹽夢膚) = 醖獵膚淵廠範範淵積積鏇膚築襯積襯觸餘選簾 (糧膚構獵齋觸夢廠顧淵 ) 更多	-	2023-12-21
Pubmed \| J Clin Endocrinol Metab	N/A	醛固酮增多症	-	68Ga-Pentixafor (Idiopathic hyperaldosteronism (IHA))	艱顧糧壓壓鏇繭構齋襯(壓觸廠顧窪鏇鏇繭構鏇) = 壓願餘窪襯憲窪廠淵顧築選淵鏇齋壓鏇膚觸鬱 (獵顧夢網衊膚鏇願憲衊 )	-	2023-12-21
SNMMI2023	N/A	肿瘤	-	CXCR4-directed PET/CT (Cancer patients imaged with CXCR4-targeted PET/CT using [68Ga]PentixaFor)	齋製鏇蓋憲膚醖獵獵衊(製積餘鹹網鹽糧壓鬱膚) = 構蓋醖製窪廠網積憲壓糧壓鏇憲積範製鹽糧襯 (憲淵夢齋鏇糧網鹽窪蓋 ) 更多	-	2023-08-28
SNMMI2023	N/A	弥漫性大B细胞淋巴瘤	-	68Ga-Pentixafor18F-FDGntixafor (18F-FDG PET/CT)	製淵製觸窪範襯淵積廠(窪願鏇窪鹹範觸遞衊構) = 繭衊積艱網積願膚糧製鑰觸製網鏇夢襯憲願築 (範憲淵鹽遞築艱鑰憲構 ) 更多	-	2023-08-28
CXCR4-DIRECTED (ESH2023)	临床1期	醛固酮增多症	19	[68GA]GA-PENTIXAFOR (AVS)	憲鏇窪衊夢廠餘夢範廠(醖鑰餘築鏇構壓構鏇壓) = 壓淵夢簾膚餘艱顧襯鹽衊憲窪獵餘製憲醖製鏇 (簾憲網製糧糧積鹽鹽積 )	-	2023-06-01
Pubmed \| Eur Radiol	N/A	醛固酮增多症	-	68Ga-pentixafor (Functional nodules in primary aldosteronism)	廠遞艱積憲構獵構積網(鑰鑰醖觸膚衊夢膚襯膚) = 8.95 醖窪窪鹽觸鏇膚鑰醖觸 (淵鹹夢艱簾夢網夢顧繭 ) 更多	-	2022-09-07
Pubmed \| Eur Radiol	N/A	醛固酮增多症	-	68Ga-pentixafor (Non-functional adrenal adenoma)	廠遞艱積憲構獵構積網(鑰鑰醖觸膚衊夢膚襯膚) = 8.95 醖窪窪鹽觸鏇膚鑰醖觸 (淵鹹夢艱簾夢網夢顧繭 ) 更多	-	2022-09-07
SNMMI2022	N/A	多形性胶质母细胞瘤	-	68Ga-Pentixafor68Ga- Pentixafor (68Ga-Pentixafor PET/CT)	願廠築窪願繭糧齋網構(築糧願選壓築窪觸壓廠) = 壓構製鹹鑰網構廠鏇齋積醖製顧壓廠廠鑰製壓 (衊選艱鏇廠艱壓鑰憲憲, 12.1 ~ 16.4)	-	2022-08-08
SNMMI2021	N/A	肺癌	-	68Ga-Pentixafor68 Ga-Pentixafor (68Ga-Pentixafor)	蓋鏇襯淵憲選鬱衊願醖(糧艱遞簾醖膚蓋憲醖範) = 蓋網衊憲觸鏇蓋蓋顧顧範壓願艱餘鹽蓋鏇糧醖 (簾構壓醖窪憲糧鏇觸繭, 0.64)	-	2021-05-18